PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Neuraxpharm
NE

Neuraxpharm

Cardiff
SME

Neuraxpharm is a leading European pharmaceutical company specializing in the treatment of central nervous system (CNS) disorders. They focus on providing innovative solutions for psychiatric and neurological conditions to improve the quality of life for patients.

neuraxpharm.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£576.4m
Live
19
Buyers
5
12m
£566.3m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts19 / 25
  • Top buyers5
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — NeuraxpharmUpdated 13 Jul 2026

At a glance · for buyers and watchdogs

Neuraxpharm has won £576.4m across 5 public-sector buyers, with 19 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
19 of 25Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 1
CNS Therapeutic SolutionsComprehensive and specialized range of CNS therapeutic solutions.

Extracted automatically from neuraxpharm.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 19 live · 6 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Branded Interim - 1 June 2026
NHS England—01 Jun 2026£529.1m1.9 yrspending
NHS National Generic Pharmaceuticals - Wave 15c
NHS England—01 Jun 2026£37.2m16 mopending
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)
NHS England3360000001 Jun 2024£0.023 yrsLive
NHS National Generics Pharmaceuticals Transition 2023_1
NHS England3360000001 Aug 2023£1.9m1.5 yrsClosed
NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals
NHS England3360000001 May 2023£6.1m2 yrsClosed
NHS National Generic Pharmaceuticals Wave 14a
NHS England3360000001 Feb 2023£2.1m2 yrsClosed
Suxamethonium invoice - Neuraxapharm letter of intent (LOI)
NHS England3300000013 Aug 2020£43k4 moClosed
Generic, Branded Generic & Proprietary Medicinal Products - Group 14
Procurement and Logistics Service33600000———Live
NHS National Branded Interim - 1 June 2026
NHS England————Live
Generic, Branded Generic & Proprietary Medicinal Products - Group 16
Procurement and Logistics Service, Business Services Organisation33600000———Live
Total live value £0.02 · mean award £23.1m1–10 of 25

Top buyers · 5 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
18 contracts
100%
since 2020
2
Procurement and Logistics Service
2 contracts
0%
3
Procurement and Logistics Service, Business Services Organisation
1 contract
0%
4
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
1 contract
0%
5
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
3 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire18 contracts
100%
Northern Ireland3 contracts
0%
Wales1 contract
0%
Scotland3 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Neuraxpharm highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
NE
Neuraxpharm
Yes£566.3m—
MA
Medequip Assistive Technology Ltd
No£82.0m2
AH
Alcura Healthcare Ltd.
No£18.7m1
IP
ITH Pharma Ltd
Yes£3.0m4
QL
Qualasept Ltd t/a Bath ASU
Yes£3.0m2
BH
BAXTER HEALTHCARE LIMITED
Yes£3.0m1
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 29 Aug 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
10918621
Status
Active
Type
Private limited
Incorporated
16 Aug 2017
Reg. office
Tudor House, 16 Cathedral Road, Cardiff, CF11 9LJ
SIC codes
46460
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • VON WÜLFING, Maximilian, Dr — director
    Appointed 10 Jan 2023
  • SLATER, Mark Anthony — director
    Appointed 10 Oct 2022
  • Permira Vii Investment Platform Limited — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
NEURAXPHARM UK LIMITED
10918621 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.